Breast carcinoma in situ
diseaseOn this page
Also known as breast cancer in situbreast cancer stage 0breast in situ carcinomacarcinoma in situ of breastcarcinoma in situ of the breastin situ breast cancernon-infiltrating breast carcinomanon-infiltrating carcinoma of breastnon-infiltrating carcinoma of the breastnon-invasive breast carcinomanon-invasive carcinoma of breastnon-invasive carcinoma of the breaststage 0 breast cancerstage 0 breast cancer aJCC v6stage 0 breast cancer aJCC v6 and v7stage 0 breast cancer aJCC v7stage 0 breast carcinomastage 0 breast carcinoma in situstage 0 carcinoma of breast
Summary
Breast carcinoma in situ (MONDO:0004658) is a cancer and 51 clinical trials. Top therapeutic interventions include toremifene, exemestane, and anastrozole. A subtype of in situ carcinoma — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Classification: Cancer
- Clinical trials: 51
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | breast carcinoma in situ |
| Mondo ID | MONDO:0004658 |
| MeSH | D000071960 |
| DOID | DOID:8791 |
| ICD-10-CM | D05 |
| ICD-11 | 1264360394 |
| NCIT | C3641 |
| SNOMED CT | 189336000 |
| UMLS | C0154084 |
| MedGen | 57817 |
| Anatomy (UBERON) | UBERON:0000310 |
| Is cancer (heuristic) | yes |
Also known as: breast cancer in situ · breast cancer stage 0 · breast carcinoma in situ · breast in situ carcinoma · carcinoma in situ of breast · carcinoma in situ of the breast · in situ breast cancer · non-infiltrating breast carcinoma · non-infiltrating carcinoma of breast · non-infiltrating carcinoma of the breast · non-invasive breast carcinoma · non-invasive carcinoma of breast · non-invasive carcinoma of the breast · stage 0 breast cancer · stage 0 breast cancer aJCC v6 · stage 0 breast cancer aJCC v6 and v7 · stage 0 breast cancer aJCC v7 · stage 0 breast carcinoma · stage 0 breast carcinoma in situ · stage 0 carcinoma of breast (+1 more)
Disease family
This is a subtype of in situ carcinoma. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.
Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › cancer › carcinoma › in situ carcinoma › breast carcinoma in situ
Related subtypes (20): oral cavity carcinoma in situ, pharynx carcinoma in situ, gall bladder carcinoma in situ, adenocarcinoma in situ, nasal cavity carcinoma in situ, skin carcinoma in situ, eye carcinoma in situ, lung carcinoma in situ, squamous carcinoma in situ, larynx carcinoma in situ, intestine carcinoma in situ, bladder carcinoma in situ, esophagus carcinoma in situ, uterus carcinoma in situ, liver carcinoma in situ, stomach carcinoma in situ, kidney carcinoma in situ, grade III prostatic intraepithelial neoplasia, carcinoma in situ of ureter, carcinoma in situ of urethra
Subtypes (4): lobular neoplasia, breast apocrine carcinoma in situ, ductal breast carcinoma in situ, ductal breast carcinoma in situ and lobular carcinoma in situ
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
No tiered GWAS variants or ClinVar records for this disease.
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
Drugs indicated for this disease
0 approved, 1 in late-stage (phase 3) trials. Disease-direct ChEMBL indications, not inferred from the associated-gene cohort below.
| Drug | Development status |
|---|---|
| Pembrolizumab | Phase 3 (in late-stage trials) |
Earlier-phase candidates (phase 2, investigational — efficacy not yet established): Cimetidine, Dexamethasone, Diphenhydramine, Exemestane, Famotidine, Paclitaxel, Ranitidine.
Clinical trials & evidence
Clinical trials
Clinical trials: 51.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| Not specified | 37 |
| PHASE2 | 6 |
| PHASE4 | 2 |
| PHASE3 | 2 |
| PHASE1 | 2 |
| PHASE2/PHASE3 | 1 |
| EARLY_PHASE1 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT07042581 | PHASE4 | RECRUITING | A Study of Revaree Plus in People With Breast Cancer |
| NCT03238703 | PHASE4 | WITHDRAWN | Endocrine Therapy in Treating Patients With HER2 Negative, Low Risk Breast Cancer |
| NCT02954874 | PHASE3 | ACTIVE_NOT_RECRUITING | Testing MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer |
| NCT01509781 | PHASE3 | UNKNOWN | Suction Drain Versus the Use of Adaptive Skin Sutures After Mastectomy ± Axillary Lymphadenectomy; a Prospective Randomised Study |
| NCT03077841 | PHASE2/PHASE3 | SUSPENDED | Hypofractionated Partial Breast Irradiation in Treating Patients With Early Stage Breast Cancer |
| NCT01245712 | PHASE2 | ACTIVE_NOT_RECRUITING | Radiation Therapy in Treating Patients With Stage 0-II Breast Cancer |
| NCT06843681 | PHASE2 | ENROLLING_BY_INVITATION | Trastuzumab Plus Taxane Neoadjuvant Therapy for HER2-Positive Breast Ductal Carcinoma In Situ (DCIS) : A Phase II Study |
| NCT02314156 | PHASE2 | COMPLETED | Transdermal or Oral Telapristone Acetate in Treating Patients Undergoing Mastectomy |
| NCT02556632 | PHASE2 | COMPLETED | Prophylactic Topical Agents in Reducing Radiation-Induced Dermatitis in Patients With Non-inflammatory Breast Cancer |
| NCT02598557 | PHASE2 | COMPLETED | Alternative Dosing of Exemestane Before Surgery in Treating Postmenopausal Patients With Stage 0-II Estrogen Positive Breast Cancer |
| NCT03345420 | PHASE2 | COMPLETED | Hypofractionated Radiation Therapy in Treating Patients With Stage 0-IIB Breast Cancer |
| NCT03317405 | PHASE1 | ACTIVE_NOT_RECRUITING | Phase I Trial of Endoxifen Gel Versus Placebo in Women Undergoing Breast Surgery |
| NCT02278965 | PHASE1 | COMPLETED | Metformin and Omega-3 Fatty Acids in Woman With a History of Early Stage Breast Cancer |
| NCT03411070 | EARLY_PHASE1 | COMPLETED | SCOUT Reflector for Tagging Lymph Nodes for Targeted Removal in Patients With Breast Cancer |
| NCT02620852 | Not specified | RECRUITING | Women Informed to Screen Depending on Measures of Risk (Wisdom Study) |
| NCT03448926 | Not specified | RECRUITING | The PREDICT Registry: |
| NCT03766009 | Not specified | ACTIVE_NOT_RECRUITING | Increasing Patients’ Engagement in Breast Cancer Surgery Decision-Making |
| NCT04074720 | Not specified | RECRUITING | Prospective Breast Cancer Biospecimen Collection |
| NCT04368702 | Not specified | RECRUITING | CONFIRM: Magnetic Resonance Guided Radiation Therapy |
| NCT04603209 | Not specified | RECRUITING | Registry for Intra-Operative Radiotherapy During Breast Conserving Surgery in Patients With Early Stage Breast Cancer |
| NCT04849871 | Not specified | ACTIVE_NOT_RECRUITING | Single Fraction Accelerated Partial Breast Irradiation vs. Five Fraction Accelerated Partial Breast Irradiation for Low-risk Stage 0 and I Breast Carcinoma |
| NCT05318274 | Not specified | ACTIVE_NOT_RECRUITING | Hypofractionated Radiation Therapy vs Standard Treatment in Breast Cancer. |
| NCT06115486 | Not specified | RECRUITING | EXERT-BCH Exercise Regimen to Improve Muscle Mass After Treatment of Breast Cancer |
| NCT06217458 | Not specified | NOT_YET_RECRUITING | The Added Value of Contrast Enhanced Mammography to Standard Mammography in Assessing the Extent of DCIS |
| NCT06234488 | Not specified | ACTIVE_NOT_RECRUITING | Multi-Institutional Transgender & Gender-Diverse Breast Cancer Study |
| NCT06275126 | Not specified | RECRUITING | Optimizing Surgical Decisions in Young Adults With Breast Cancer |
| NCT06401304 | Not specified | RECRUITING | Oncologic, Cosmetic and Patient Reported Outcomes in Value-Based Breast Surgery (OnCoPRO Value) |
| NCT06931548 | Not specified | RECRUITING | Ways of Retaining the Inframammary Fold in Implant-based Breast Surgery |
| NCT00225927 | Not specified | COMPLETED | Trial Comparing Radioactive Seed Localization to Standard Procedure for Non-palpable Breast Cancers |
| NCT00909818 | Not specified | UNKNOWN | Hypofractionated Versus Standard Fractionated Whole Breast Irradiation to Node-negative Breast Cancer Patients |
| NCT01688388 | Not specified | COMPLETED | Single Fraction Intraoperative Radiotherapy |
| NCT02159274 | Not specified | COMPLETED | Shoulder Disability and Late Symptoms Following Oncoplastic Breast Surgery |
| NCT02400060 | Not specified | COMPLETED | Telephone-Based Intervention in Increasing Adherence to Adjuvant Hormonal Therapy in Patients With Breast Cancer |
| NCT02662335 | Not specified | COMPLETED | Computerized Cognitive Retraining in Improving Cognitive Function in Breast Cancer Survivors |
| NCT02699983 | Not specified | COMPLETED | eHealth Weight Loss Program in African American Breast Cancer Survivors |
| NCT02728596 | Not specified | COMPLETED | S1415CD, Trial Assessing CSF Prescribing Effectiveness and Risk (TrACER) |
| NCT03025139 | Not specified | UNKNOWN | Mindfulness Meditation or Survivorship Education in Improving Behavioral Symptoms in Younger Stage 0-III Breast Cancer Survivors (Pathways to Wellness) |
| NCT03039140 | Not specified | COMPLETED | Cardiac Rehabilitation Program in Improving Cardiorespiratory Fitness in Stage 0-III Breast Cancer Survivors |
| NCT03050463 | Not specified | COMPLETED | Functional Magnetic Resonance Imaging in Assessing Affect Reactivity and Regulation in Patients With Stage 0-III Breast Cancer |
| NCT03052907 | Not specified | COMPLETED | Breast Screening & Patient Navigation (BSPAN2): Evaluating a De-Centralized Regional Delivery System for Rural Underserved |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| TOREMIFENE | 4 | 3 |
| EXEMESTANE | 4 | 2 |
| ANASTROZOLE | 4 | 1 |
| LETROZOLE | 4 | 1 |
| PEMBROLIZUMAB | 4 | 1 |
| TAMOXIFEN CITRATE | 4 | 1 |
| AFIMOXIFENE | 3 | 1 |
| ENDOXIFEN | 3 | 1 |
| OMEGA-3 FATTY ACIDS | 3 | 1 |
| TELAPRISTONE ACETATE | 3 | 1 |